ASHLEY LANCE: Open Payments
NPI 1629323365 · ST JOSEPH, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$864 in 42 payments from 16 companies in 2025. Trend: 2023 $558 · 2024 $677 · 2025 $864
Food & beverage: $864
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $264 |
| ABBVIE INC. | 11 | $174 |
| Astellas Pharma US Inc | 4 | $92 |
| Amgen Inc. | 3 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Lundbeck LLC | 2 | $37 |
| Novo Nordisk Inc | 2 | $33 |
| Lilly USA, LLC | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Boston Scientific Corporation | 1 | $24 |
Products named: BREZTRI, Veozah, UBRELVY, VRAYLAR, QULIPTA, AIRSUPRA, CAPLYTA, REXULTI.
Industry payments across MO — which companies pay providers there.
